A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

Purpose: PRO95780 is a fully human IgG1 monoclonal antibody that triggers the extrinsic apoptosis pathway through death receptor 5. This first-in-human study assessed the safety, tolerability, pharmacokinetics, and any early evidence of efficacy of PRO95780 in patients with advanced malignancies. Experimental Design: Target concentrations were predicted to occur at 10 mg/kg. Patients received up to eight cycles of PRO95780 i.v. using a 3+3 dose escalation design at 1 to 20 mg/kg every 14 days (every 28 days in cycle 1; stage 1), with cohort expansion at either the maximum tolerated dose or 10 mg/kg, whichever was lower (stage 2). Patients were evaluated for response every other cycle. Results: The maximum tolerated dose was not reached within this study. Four (8%) of 50 patients reported adverse events of greater than grade 2 at least possibly related to PRO95780, including 2 patients with reversible grade 3 transaminase elevation. The mean terminal half-life was 8.8 to 19.3 days, with dose-dependent increases in exposure (peak plasma concentration and area under the concentration) across 1 to 15 mg/kg. Most patients treated with 10 mg/kg or above achieved trough concentration above the target efficacious concentration at day 15 with moderate accumulation after multiple doses. No objective responses occurred, although three minor responses were observed in patients with colorectal and granulosa cell ovarian cancers (each treated with 4 mg/kg) and chondrosarcoma (10 mg/kg). Conclusions: PRO95780 is safe and well tolerated at doses up to 20 mg/kg. Evidence of activity was noted in several different tumor types at 4 and 10 mg/kg. Pharmacokinetic analysis supports a dosing regimen of 10 to 15 mg/kg every 2 to 3 weeks. Clin Cancer Res; 16(4); 1256–63

[1]  A. Ashkenazi,et al.  Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma , 2007 .

[2]  A. Oza,et al.  A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[3]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[4]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[5]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[6]  D. Vaux,et al.  Apoptosis in the development and treatment of cancer. , 2004, Carcinogenesis.

[7]  R. Herbst,et al.  Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Ford,et al.  Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. , 2007, Cancer research.

[9]  J. Posey,et al.  A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas , 2008 .

[10]  G. Screaton,et al.  Expression of TRAIL and TRAIL receptors in normal and malignant tissues , 2005, Cell Research.

[11]  D. Camidge Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. , 2008, Expert opinion on biological therapy.

[12]  A. Ashkenazi,et al.  Directing cancer cells to self-destruct with pro-apoptotic receptor agonists , 2008, Nature Reviews Drug Discovery.

[13]  R. Herbst,et al.  A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Jonathan M Lee,et al.  Apoptosis, cancer and the p53 tumour suppressor gene , 1995, Cancer and Metastasis Reviews.

[15]  D. Lawrence,et al.  Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival , 2004, Cancer Research.

[16]  G. Packham,et al.  Regulation of tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐induced apoptosis in Burkitt's lymphoma cell lines , 2003, British journal of haematology.

[17]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[18]  D. Lawrence,et al.  Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival , 2008, Clinical Cancer Research.

[19]  R. K Srivastava TRAIL/Apo-2L: mechanisms and clinical applications in cancer. , 2001, Neoplasia.

[20]  H. Hollema,et al.  Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. , 2005, European journal of cancer.

[21]  R. Herbst,et al.  First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors , 2007 .

[22]  D. Lawrence,et al.  Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 , 2008, Cell Death and Differentiation.

[23]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[24]  R. Plummer,et al.  Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers , 2007, Clinical Cancer Research.

[25]  de Elisabeth G. E. Vries,et al.  Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors , 2008 .

[26]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[27]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[28]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.